case_images: PMC2193107_01
case_images: Progression of inflammatory lesions appearing around pigmented areas of skin from days 5-7 after T cell infusion 3.
case_images: JEM001237.f2.jpg
case_images: PMC2193107_01_JEM001237.f2.jpg
case_images: F2
case_images: Some lesions developed into bullae and underwent a vitiliginous change, whereas others began to spread and coalesce over the next 3 d to cover most of her back and upper arms (Fig. 2).
case_images: Immunohistochemical staining of inflammatory lesion from skin biopsy obtained on day 6. Hematoxylin and eosin stain demonstrates intense lymphocytic infiltrate in the dermal-epidermal junction in the area of melanocytic nevus. Immunohistochemical staining of the same section demonstrates a predominant population of CD4-CD8+ lymphocytes in infiltrate.
case_images: JEM001237.f3.jpg
case_images: PMC2193107_01_JEM001237.f3.jpg
case_images: F3
case_images: Histologically, the skin displayed an intense inflammatory infiltrate composed of lymphocytes centered around the dermal-epidermal junction (Fig. 3).
case_images: Characterization of lymphocytes harvested from skin biopsy obtained day 6 after CTL infusion 3 (left) and from tumor biopsy (right). Same skin sample as in Fig. 3. Flow cytometry analysis (left) using PE-conjugated M27 tetramer or an irrelevant (T369) tetramer and anti-CD8-FITC antibody demonstrates a population of MART-1-specific CTL clones representing >28% of the CD8+ lymphocyte population recovered from the skin biopsy. Flow cytometry analysis (right) of tumor biopsy demonstrates MART-1-specific CTL staining comprising >37% of CD8+ lymphocytes in tumor sample.
case_images: JEM001237.f4.jpg
case_images: PMC2193107_01_JEM001237.f4.jpg
case_images: F4
case_images: Staining of these cells using peptide-MHC tetramers revealed a substantial proportion (28.2%) of CD8+ T cells binding specifically to the M27 peptide-MHC tetramer (Fig. 4). Approximately 38% of CD8+ lymphocytes from this specimen stained with the MART-1 (M27) peptide-MHC tetramer but not with control tetramers (tyrosinase and gp100), demonstrating that infused MART-1-specific T cells localized not only to normal melanocytes in the skin but also to tumor sites (Fig. 4).